No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Hutchmed China announced on Thursday that it was set to receive a $20m milestone payment from its partner Takeda, after sales of 'Fruzaqla', or fruquintinib, surpassed $200m.
The AIM-traded firm said the drug, used to treat metastatic colorectal cancer (CRC), generated $203m in net sales in the nine months through September.
It said the milestone payment marked its first commercial milestone revenue.
Takeda holds exclusive rights to develop, manufacture and commercialise fruquintinib outside mainland China, Hong Kong, and Macau under the Fruzaqla brand.
Since receiving FDA approval in November, Takeda has expanded its regulatory approvals globally, securing authorisations in the EU, Switzerland, Canada, Japan, the UK, Argentina, Australia, and Singapore in 2024.
Applications were also progressing in additional markets as Takeda broadened access to the treatment across multiple jurisdictions.
"The achievement of $200m in sales is a testament to Takeda's commercial strength in launching global brands, the clinical benefit of fruquintinib and the success of our partnership strategy for commercialising our medicines outside of China," said chief executive and chief scientific officer Dr Weiguo Su.
"Receiving the $20m milestone payment will strengthen our balance sheet as we look to expand the use of fruquintinib into new indications, and highlights our strategy of global partnerships across our broad pipeline."
At 1058 GMT, shares in Hutchmed China were down 2.05% at 286p.
Reporting by Josh White for Sharecast.com.
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.
